Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Notes Payables (2016 - 2025)

BioCorRx's Notes Payables history spans 16 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Notes Payables rose 20.15% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 20.15%, while the annual FY2024 figure was $1.3 million, 121.39% up from the prior year.
  • Notes Payables for Q3 2025 was $1.5 million at BioCorRx, roughly flat from $1.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $1.5 million in Q3 2025 and bottomed at $21480.0 in Q1 2021.
  • The 5-year median for Notes Payables is $606750.0 (2023), against an average of $696076.5.
  • The largest annual shift saw Notes Payables skyrocketed 3578.35% in 2021 before it crashed 71.97% in 2022.
  • A 5-year view of Notes Payables shows it stood at $790110.0 in 2021, then plummeted by 62.33% to $297602.0 in 2022, then soared by 103.88% to $606750.0 in 2023, then soared by 121.39% to $1.3 million in 2024, then increased by 15.23% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Notes Payables are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.5 million (Q1 2025).